Literature DB >> 2502496

Recombinant IL-4 and IFN-gamma activate locomotor capacity in human B lymphocytes.

P C Wilkinson1, L N Islam.   

Abstract

Recombinant human interleukin-4 (IL-4) or interferon-gamma (IFN-gamma) were added to cultures of B-enriched human lymphocytes from normal blood, or to the lymphocytes from five patients with chronic lymphocytic leukaemia (CLL). IL-4 and IFN-gamma caused the B lymphocytes to acquire locomotor capacity, as judged by morphological polarization and invasion of collagen gels. This was detectable in normal B cells within a few hours of culture and fully developed by 24-48 hr. It was inhibited by the presence of cyclosporin A. The responding, motile cells also increased in size. These findings suggest that B lymphocytes acquire locomotor capacity early in growth, as the cells move from G0 to G1. IL-4 or IFN-gamma had no direct effect in polarizing lymphocytes in a short-term (30-min) assay, thus they do not behave like chemotactic factors. They slowly increase the proportion of locomotor cells in B-lymphocyte populations, and these motile cells respond by polarization to factors released by the growing cells into the medium.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502496      PMCID: PMC1385264     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  A proposal for the definition of terms related to locomotion of leucocytes and other cells.

Authors:  H U Keller; P C Wilkinson; M Abercrombie; E L Becker; J G Hirsch; M E Miller; W Scottramsey; S H Zigmond
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

2.  B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes.

Authors:  S Romagnani; M G Giudizi; R Biagiotti; F Almerigogna; C Mingari; E Maggi; C M Liang; L Moretta
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

3.  The locomotor capacity of human lymphocytes and its enhancement by cell growth.

Authors:  P C Wilkinson
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

4.  Anchorage and lymphocyte function: collagen and the maintenance of motile shape in T cells.

Authors:  K G Sundqvist; P Otteskog
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

5.  Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines.

Authors:  P Harris; P Ralph
Journal:  J Leukoc Biol       Date:  1985-04       Impact factor: 4.962

6.  Activation and proliferation signals in mouse B cells. II. Evidence for activation (G0 to G1) signals differing in sensitivity to cyclosporine.

Authors:  G G Klaus; C M Hawrylowicz
Journal:  Eur J Immunol       Date:  1984-03       Impact factor: 5.532

7.  Induction of human T lymphocyte motility by interleukin 2.

Authors:  H Kornfeld; J S Berman; D J Beer; D M Center
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Lymphocyte locomotion and attachment on two-dimensional surfaces and in three-dimensional matrices.

Authors:  W S Haston; J M Shields; P C Wilkinson
Journal:  J Cell Biol       Date:  1982-03       Impact factor: 10.539

9.  Effects of phorbol esters on shape and locomotion of human blood lymphocytes.

Authors:  P C Wilkinson; J M Lackie; W S Haston; L N Islam
Journal:  J Cell Sci       Date:  1988-08       Impact factor: 5.285

10.  The mediator of cellular immunity. VII. Localization of sensitized lymphocytes in inflammatory exudates.

Authors:  D D McGregor; P S Logie
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  9 in total

1.  Locomotor properties of human germinal centre B cells: activation by anti-CD40 and IL-4 allows chemoattraction by anti-immunoglobulin.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

2.  Relation between locomotion, chemotaxis and clustering of immune cells.

Authors:  P C Wilkinson
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

3.  Chemotaxis of human B lymphocytes to anti-IgD.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

4.  FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes.

Authors:  P C Wilkinson; E A Watson
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

5.  Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.

Authors:  Qiliang Cai; Subhash C Verma; Ji-Young Choi; Michelle Ma; Erle S Robertson
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

6.  Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

Review 7.  New PARP targets for cancer therapy.

Authors:  Sejal Vyas; Paul Chang
Journal:  Nat Rev Cancer       Date:  2014-06-05       Impact factor: 60.716

8.  Interleukin-10 inhibits motility in murine and human B lymphocytes.

Authors:  B Clinchy; P Björck; S Paulie; G Möller
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

9.  Efficient antigen presentation of soluble, but not particulate, antigen in the absence of Wiskott-Aldrich syndrome protein.

Authors:  Lisa Westerberg; Robert P A Wallin; Gediminas Greicius; Hans-Gustaf Ljunggren; Eva Severinson
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.